Health Care·Biotechnology·$5.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.15 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.15 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a cautious approach regarding current market conditions. They emphasized their commitment to long-term strategies without providing immediate guidance.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The focus remains on long-term growth and product development.
Celcuity Inc's earnings report showed a loss per share of $-0.15, but no revenue figures were disclosed. The stock fell by 3.08% following the announcement, reflecting investor concerns over the lack of guidance and specific financial metrics. This cautious sentiment may impact investor confidence in the company's near-term performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
BWX TECHNOLOGIES INC
Feb 25, 2019